Feds asked to OK what could be the first COVID-19 antiviral pill
By
Alicia Lasek
Oct 12, 2021
If authorized for emergency use, certain patients could take molnupiravir at home after COVID-19 diagnosis, the drug’s developers said.
Recovered COVID-19 patients may have a booster shot edge, research finds
By
Alicia Lasek
Oct 12, 2021
Recovered COVID-19 patients may gain more protection from a booster shot when compared to their peers who haven’t caught the virus. Researchers say the findings could help determine ideal booster vaccine...
Clinical briefs for Tuesday, Oct. 12
By
Alicia Lasek
Oct 12, 2021
As antipsychotic stewardship backslides in nursing homes, risks mount … Don’t pause osteoporosis drug risedronate for more than two years, new research suggests … CDC advisers plan review of more...
C. diff may sneak in on soles of shoes, sampling study shows
By
Alicia Lasek
Oct 08, 2021
Community exposure to the superbug Clostridiodes difficile may be more common than previously thought, with a surprising amount of spores carried on the soles of shoes, researchers say.
No safety issues: Fluzone shot can be co-administered with a Moderna COVID vaccine booster, Sanofi says
By
Alicia Lasek
Oct 08, 2021
Older adults have the same immune response to each drug when they are co-administered as when given separately. This is also true of safety and tolerability, the drugmaker says.
A first? COVID antibody therapy with full-year protection is up for FDA authorization
By
Alicia Lasek
Oct 08, 2021
Drugmaker AstraZeneca has asked the FDA to authorize what it says could be the first long-acting monoclonal antibody drug therapy for the prevention of COVID-19 in at-risk patients.
Clinical briefs for Friday, Oct. 8
By
Alicia Lasek
Oct 08, 2021
Infection control report puts organizational challenges and best practices under the microscope … Coordinator turnover threatens to cut into reimbursement: survey … Seniors account for disproportionate...
Post-COVID depression responds better than expected to SSRI drugs, study finds
By
Alicia Lasek
Oct 07, 2021
The findings may suggest a path to relief for recovered COVID-19 patients, investigators say. About 40% of these patients develop depression within six months of infection, they report.
J&J asks for booster go-ahead, says second vaccine dose provides 100 percent COVID protection
By
Alicia Lasek
Oct 07, 2021
A second shot of Johnson & Johnson’s vaccine provides 100% protection against severe or critical COVID-19 when given two months after a first dose, according to new data.
Pilot program aims to improve quality of post-fracture care for patients with osteoporosis
By
Alicia Lasek
Oct 07, 2021
The National Osteoporosis Foundation and two U.S. health systems are collaborating to create what they call a post-fracture care pathway to increase the number of patients who receive bone health treatment...